查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386335

B 细胞淋巴瘤治疗市场报告：2030 年趋势、预测与竞争分析

B-Cell Lymphoma Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

B 细胞淋巴瘤治疗的趋势和预测

预计到 2030 年，全球 B 细胞淋巴瘤治疗市场将达到 102.8 亿美元，2024 年至 2030 年复合年增长率为 7.8%。该市场的主要驱动因素是 B 细胞淋巴瘤盛行率的增加和治疗方案的不断进步。全球B细胞淋巴瘤治疗市场前景广阔，医院、专科诊所及家庭医疗保健市场蕴含商机。

B 细胞淋巴瘤治疗市场洞察

Lucintel 预测，由于 B 细胞淋巴瘤病例数的增加和盛行率的增加，在预测期内，瀰漫性大 B 细胞淋巴瘤仍将是最大的部分。

医院可能仍然是该市场中最大的部分，因为它们提供必要的设备和专业知识来进行广泛的 B 细胞淋巴瘤治疗。

由于北美拥有发达的医疗保健系统，可以获得最新的 B 细胞淋巴瘤治疗方法，预计在预测期内仍将是最大的市场。

市场规模/估计：以金额（B 美元）估计 B 细胞淋巴瘤治疗的市场规模。

趋势和预测分析：各个细分市场和地区的市场趋势（2018-2023）和预测（2024-2030）。

細項分析：按类型、最终用途、配销通路和地区金额（十亿美元）估计 B 细胞淋巴瘤治疗市场规模。

区域分析：北美、欧洲、亚太地区和世界其他地区 B 细胞淋巴瘤治疗市场的区域细分。

成长机会：按类型、最终用途、配销通路和地区分析 B 细胞淋巴瘤治疗市场的成长机会。

策略分析： B细胞淋巴瘤治疗市场併购、新产品开发、竞争形势等。

基于波特五力模型的产业竞争实力分析。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球B细胞淋巴瘤治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球B细胞淋巴瘤治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球 B 细胞淋巴瘤治疗市场
    • 瀰漫性大B细胞淋巴瘤
    • 淋巴浆细胞淋巴瘤
    • 毛细胞白血病
    • 原发性中枢神经系统淋巴瘤
    • 原发性眼内淋巴瘤
    • 其他的
  • 按最终用途分類的全球 B 细胞淋巴瘤治疗市场
    • 医院
    • 专科诊所
    • 家庭保健
    • 其他的
  • 按配销通路的全球 B 细胞淋巴瘤治疗市场
    • 直接竞标
    • 医院药房
    • 零售药房
    • 线上药房
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球B细胞淋巴瘤治疗市场（按地区）
  • 北美B细胞淋巴瘤治疗市场
  • 欧洲B细胞淋巴瘤治疗市场
  • 亚太B细胞淋巴瘤治疗市场
  • 其他地区B细胞淋巴瘤治疗市场

第五章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球 B 细胞淋巴瘤治疗市场成长机会
    • 全球 B 细胞淋巴瘤治疗市场成长机会（依最终用途）
    • 全球 B 细胞淋巴瘤治疗市场成长机会（按配销通路）
    • 全球 B 细胞淋巴瘤治疗市场按地区成长机会
  • 全球B细胞淋巴瘤治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球 B 细胞淋巴瘤治疗市场的产能
    • 全球B细胞淋巴瘤治疗市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • AstraZeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck
简介目录

B-Cell Lymphoma Treatment Trends and Forecast

The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets. The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030 with a CAGR of 7.8% from 2024 to 2030. The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

A more than 150-page report is developed to help in your business decisions.

B-Cell Lymphoma Treatment by Segment

The study includes a forecast for the global B-cell lymphoma treatment by type, end use, distribution channel, and region.

B-Cell Lymphoma Treatment Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diffuse Large B-Cell Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Hairy Cell Leukemia
  • Primary Central Nervous System Lymphoma
  • Primary Intraocular Lymphoma
  • Others

B-Cell Lymphoma Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Others

B-Cell Lymphoma Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Direct Tender
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

B-Cell Lymphoma Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of B-Cell Lymphoma Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies B-cell lymphoma treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the B-cell lymphoma treatment companies profiled in this report include-

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

B-Cell Lymphoma Treatment Market Insights

Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Within this market, hospital will remain the largest segment as it provides necessary equipment and expertise to perform a wide range of B-cell lymphoma treatments.

North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Features of the Global B-Cell Lymphoma Treatment Market

Market Size Estimates: B-cell lymphoma treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: B-cell lymphoma treatment market size by type, end use, distribution channel, and region in terms of value ($B).

Regional Analysis: B-cell lymphoma treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, end uses, distribution channels, and regions for the B-cell lymphoma treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the B-cell lymphoma treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the B-cell lymphoma treatment market size?

Answer: The global B-cell lymphoma treatment market is expected to reach an estimated $10.28 billion by 2030.

Q.2 What is the growth forecast for B-cell lymphoma treatment market?

Answer: The global B-cell lymphoma treatment market is expected to grow with a CAGR of 7.8% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the B-cell lymphoma treatment market?

Answer: The major drivers for this market are growing incidence of B-cell lymphomas and on-going advancements in the treatment options.

Q4. What are the major segments for B-cell lymphoma treatment market?

Answer: The future of the global B-cell lymphoma treatment market looks promising with opportunities in the hospital, specialty clinic, and home healthcare markets.

Q5. Who are the key B-cell lymphoma treatment market companies?

Answer: Some of the key B-cell lymphoma treatment companies are as follows:

  • Pfizer
  • Celgene Corporation
  • Eli Lilly
  • Novartis
  • Genentech
  • Astrazeneca
  • F. Hoffmann-La Roche
  • Eisai
  • Amgen
  • Merck

Q6. Which B-cell lymphoma treatment market segment will be the largest in future?

Answer: Lucintel forecasts that diffuse large B-cell lymphoma is expected to witness highest growth over the forecast period due to fast-growing lymphoma that can affect people of all ages, but it is most common in older adults.Lucintel forecasts that diffuse large B-cell lymphoma will remain the largest segment over the forecast period due to increase number of cases and growing prevalence of B-cell lymphomas.

Q7. In B-cell lymphoma treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to presence of well-developed healthcare system with access to the latest B-cell lymphoma treatments in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the B-cell lymphoma treatment market by type (diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, primary central nervous system lymphoma, primary intraocular lymphoma, and others), end use (hospitals, specialty clinics, home healthcare, and others), distribution channel (direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global B-Cell Lymphoma Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global B-Cell Lymphoma Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global B-Cell Lymphoma Treatment Market by Type
    • 3.3.1: Diffuse Large B-Cell Lymphoma
    • 3.3.2: Lymphoplasmacytic Lymphoma
    • 3.3.3: Hairy Cell Leukemia
    • 3.3.4: Primary Central Nervous System Lymphoma
    • 3.3.5: Primary Intraocular Lymphoma
    • 3.3.6: Others
  • 3.4: Global B-Cell Lymphoma Treatment Market by End Use
    • 3.4.1: Hospitals
    • 3.4.2: Specialty Clinics
    • 3.4.3: Home Healthcare
    • 3.4.4: Others
  • 3.5: Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 3.5.1: Direct Tender
    • 3.5.2: Hospital Pharmacy
    • 3.5.3: Retail Pharmacy
    • 3.5.4: Online Pharmacy
    • 3.5.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global B-Cell Lymphoma Treatment Market by Region
  • 4.2: North American B-Cell Lymphoma Treatment Market
    • 4.2.2: North American B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.3: European B-Cell Lymphoma Treatment Market
    • 4.3.1: European B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.3.2: European B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.4: APAC B-Cell Lymphoma Treatment Market
    • 4.4.1: APAC B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.4.2: APAC B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others
  • 4.5: ROW B-Cell Lymphoma Treatment Market
    • 4.5.1: ROW B-Cell Lymphoma Treatment Market by Type: Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Hairy Cell Leukemia, Primary Central Nervous System Lymphoma, Primary Intraocular Lymphoma, and Others
    • 4.5.2: ROW B-Cell Lymphoma Treatment Market by End Use: Hospitals, Specialty Clinics, Home Healthcare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Type
    • 6.1.2: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by End Use
    • 6.1.3: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global B-Cell Lymphoma Treatment Market by Region
  • 6.2: Emerging Trends in the Global B-Cell Lymphoma Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global B-Cell Lymphoma Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global B-Cell Lymphoma Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Celgene Corporation
  • 7.3: Eli Lilly
  • 7.4: Novartis
  • 7.5: Genentech
  • 7.6: AstraZeneca
  • 7.7: F. Hoffmann-La Roche
  • 7.8: Eisai
  • 7.9: Amgen
  • 7.10: Merck